Apolipoprotein E mimetic is more effective than apolipoprotein A-I mimetic in reducing lesion formation in older female apo E null mice.

Two apolipoprotein E mimetic peptides with similar cholesterol reducing properties exhibit differential atheroprotective effects in LDL-R null mice. Atherosclerosis (2012) 1.50

Molecules that mimic apolipoprotein A-I: potential agents for treating atherosclerosis. J Med Chem (2013) 0.98

Anti-inflammatory and cholesterol-reducing properties of apolipoprotein mimetics: a review. J Lipid Res (2014) 0.92

An apolipoprotein A-I mimetic peptide designed with a reductionist approach stimulates reverse cholesterol transport and reduces atherosclerosis in mice. PLoS One (2013) 0.89

Apolipoprotein A-I mimetics. Curr Opin Lipidol (2014) 0.85

What does HDL do? A new mechanism to slow atherogenesis--but a new problem in type 2 diabetes mellitus. Atherosclerosis (2012) 0.78

A human apolipoprotein E mimetic peptide reduces atherosclerosis in aged apolipoprotein E null mice. Am J Transl Res (2016) 0.77

High-density lipoprotein mimetics: promises and challenges. Biochem J (2015) 0.76

Apolipoprotein E mimetic is more effective than apolipoprotein A-I mimetic in reducing lesion formation in older female apo E null mice: a commentary. Atherosclerosis (2012) 0.75

Cationic peptide mR18L with lipid lowering properties inhibits LPS-induced systemic and liver inflammation in rats. Biochem Biophys Res Commun (2013) 0.75

ApoE-deficient mice are a model of lipoprotein oxidation in atherogenesis. Demonstration of oxidation-specific epitopes in lesions and high titers of autoantibodies to malondialdehyde-lysine in serum. Arterioscler Thromb (1994) 3.11

Prevention of atherosclerosis in apolipoprotein E-deficient mice by bone marrow transplantation. Science (1995) 3.10

Oral administration of an Apo A-I mimetic Peptide synthesized from D-amino acids dramatically reduces atherosclerosis in mice independent of plasma cholesterol. Circulation (2002) 2.91

Purification of human serum paraoxonase/arylesterase. Evidence for one esterase catalyzing both activities. Drug Metab Dispos (1991) 2.51

A cell-free assay for detecting HDL that is dysfunctional in preventing the formation of or inactivating oxidized phospholipids. J Lipid Res (2001) 2.38

Apolipoprotein E promotes the regression of atherosclerosis independently of lowering plasma cholesterol levels. Arterioscler Thromb Vasc Biol (2004) 2.29

In vitro stimulation of HDL anti-inflammatory activity and inhibition of LDL pro-inflammatory activity in the plasma of patients with end-stage renal disease by an apoA-1 mimetic peptide. Kidney Int (2009) 2.09

Effects of D-4F on vasodilation and vessel wall thickness in hypercholesterolemic LDL receptor-null and LDL receptor/apolipoprotein A-I double-knockout mice on Western diet. Circ Res (2005) 2.06

Studies of synthetic peptide analogs of the amphipathic helix. Structure of complexes with dimyristoyl phosphatidylcholine. J Biol Chem (1985) 1.89

Somatic gene transfer of human ApoA-I inhibits atherosclerosis progression in mouse models. Circulation (1999) 1.88

D-4F induces heme oxygenase-1 and extracellular superoxide dismutase, decreases endothelial cell sloughing, and improves vascular reactivity in rat model of diabetes. Circulation (2005) 1.78

Treatment of severe hypercholesterolemia in apolipoprotein E-deficient mice by bone marrow transplantation. J Clin Invest (1995) 1.72

Structural requirements for antioxidative and anti-inflammatory properties of apolipoprotein A-I mimetic peptides. J Lipid Res (2007) 1.65

Rabbit serum paraoxonase 3 (PON3) is a high density lipoprotein-associated lactonase and protects low density lipoprotein against oxidation. J Biol Chem (2000) 1.62

Only the two end helixes of eight tandem amphipathic helical domains of human apo A-I have significant lipid affinity. Implications for HDL assembly. Arterioscler Thromb Vasc Biol (1996) 1.55

A new synthetic class A amphipathic peptide analogue protects mice from diet-induced atherosclerosis. J Lipid Res (2001) 1.53

Structure and function of HDL mimetics. Arterioscler Thromb Vasc Biol (2009) 1.40

Intravenous infusion of apolipoprotein E accelerates clearance of plasma lipoproteins in rabbits. J Clin Invest (1989) 1.35

Effect of end group blockage on the properties of a class A amphipathic helical peptide. Proteins (1993) 1.19

L-4F, an apolipoprotein A-1 mimetic, restores nitric oxide and superoxide anion balance in low-density lipoprotein-treated endothelial cells. Circulation (2003) 1.18

Binding of amphiphilic peptides to phospholipid/cholesterol unilamellar vesicles: a model for protein--cholesterol interaction. Proc Natl Acad Sci U S A (1981) 1.15

Apolipoprotein E mimetic Peptide dramatically lowers plasma cholesterol and restores endothelial function in watanabe heritable hyperlipidemic rabbits. Circulation (2005) 1.14

Synthetic peptide analogs of apolipoproteins. Methods Enzymol (1986) 1.13

Apolipoprotein A-I deficiency results in markedly increased atherosclerosis in mice lacking the LDL receptor. Arterioscler Thromb Vasc Biol (2003) 1.12

The receptor binding domain of apolipoprotein E, linked to a model class A amphipathic helix, enhances internalization and degradation of LDL by fibroblasts. Biochemistry (2000) 1.10

Effect of an arginine-rich amphipathic helical peptide on plasma cholesterol in dyslipidemic mice. Atherosclerosis (2003) 1.03

Anti-inflammatory and recycling properties of an apolipoprotein mimetic peptide, Ac-hE18A-NH(2). Atherosclerosis (2009) 1.02

Apolipoprotein E mimetics and cholesterol-lowering properties. Am J Cardiovasc Drugs (2011) 0.98

Chemical synthesis and biochemical properties of peptide fragments of apolipoprotein-alanine. Proc Natl Acad Sci U S A (1973) 0.97

Two adjacent domains (141-150 and 151-160) of apoE covalently linked to a class A amphipathic helical peptide exhibit opposite atherogenic effects. Atherosclerosis (2010) 0.97

Interaction of native and modified low-density lipoproteins with extracellular matrix. Curr Opin Lipidol (2000) 0.95

Apolipoprotein-E degradation in human very low density lipoproteins by plasma protease(s): chemical and biological consequences. Biochem Biophys Res Commun (1982) 0.93

Sidedness of interfacial arginine residues and anti-atherogenicity of apolipoprotein A-I mimetic peptides. J Lipid Res (2012) 0.93

Cationic domain 141-150 of apoE covalently linked to a class A amphipathic helix enhances atherogenic lipoprotein metabolism in vitro and in vivo. J Lipid Res (2001) 0.91

Inhibition of atherosclerosis in apolipoprotein-E-deficient mice following muscle transduction with adeno-associated virus vectors encoding human apolipoprotein-E. Gene Ther (2002) 0.91

Drugs in development: targeting high-density lipoprotein metabolism and reverse cholesterol transport. Curr Opin Cardiol (2005) 0.85

Emerging role of high-density lipoprotein in the prevention of cardiovascular disease. Drug Discov Today (2005) 0.82

Antiinflammatory properties of HDL. Circ Res (2004) 5.41

Nucleotide sequence of the gene for a fibronectin-binding protein from Staphylococcus aureus: use of this peptide sequence in the synthesis of biologically active peptides. Proc Natl Acad Sci U S A (1989) 3.94

The amphipathic helix in the exchangeable apolipoproteins: a review of secondary structure and function. J Lipid Res (1992) 3.74

Amphipathic helix motif: classes and properties. Proteins (1990) 3.52

Oral administration of an Apo A-I mimetic Peptide synthesized from D-amino acids dramatically reduces atherosclerosis in mice independent of plasma cholesterol. Circulation (2002) 2.91

Oral D-4F causes formation of pre-beta high-density lipoprotein and improves high-density lipoprotein-mediated cholesterol efflux and reverse cholesterol transport from macrophages in apolipoprotein E-null mice. Circulation (2004) 2.62

The myeloperoxidase product hypochlorous acid oxidizes HDL in the human artery wall and impairs ABCA1-dependent cholesterol transport. Proc Natl Acad Sci U S A (2004) 2.39

Apolipoprotein A-I mimetic peptides. Arterioscler Thromb Vasc Biol (2005) 2.33

Anti-inflammatory apoA-I-mimetic peptides bind oxidized lipids with much higher affinity than human apoA-I. J Lipid Res (2008) 2.27

Normal high density lipoprotein inhibits three steps in the formation of mildly oxidized low density lipoprotein: steps 2 and 3. J Lipid Res (2000) 2.22

Effects of increasing hydrophobicity on the physical-chemical and biological properties of a class A amphipathic helical peptide. J Lipid Res (2001) 2.11

Normal high density lipoprotein inhibits three steps in the formation of mildly oxidized low density lipoprotein: step 1. J Lipid Res (2000) 2.05

D-4F and statins synergize to render HDL antiinflammatory in mice and monkeys and cause lesion regression in old apolipoprotein E-null mice. Arterioscler Thromb Vasc Biol (2005) 1.99

Lipoprotein inflammatory properties and serum amyloid A levels but not cholesterol levels predict lesion area in cholesterol-fed rabbits. J Lipid Res (2007) 1.96

Concern Crystal structure of human apolipoprotein A-I: insights into its protective effect against cardiovascular diseases. Proc Natl Acad Sci U S A (2006) 1.92

Studies of synthetic peptide analogs of the amphipathic helix. Structure of complexes with dimyristoyl phosphatidylcholine. J Biol Chem (1985) 1.89

The amphipathic alpha helix: a multifunctional structural motif in plasma apolipoproteins. Adv Protein Chem (1994) 1.89

A sensitive and convenient method for lipoprotein profile analysis of individual mouse plasma samples. J Lipid Res (2000) 1.83

Structural models of human apolipoprotein A-I: a critical analysis and review. Biochim Biophys Acta (2001) 1.80

The role of dysfunctional HDL in atherosclerosis. J Lipid Res (2008) 1.73

Apolipoprotein A-I (apoA-I) and apoA-I mimetic peptides inhibit tumor development in a mouse model of ovarian cancer. Proc Natl Acad Sci U S A (2010) 1.71

Structural requirements for antioxidative and anti-inflammatory properties of apolipoprotein A-I mimetic peptides. J Lipid Res (2007) 1.65

Only the two end helixes of eight tandem amphipathic helical domains of human apo A-I have significant lipid affinity. Implications for HDL assembly. Arterioscler Thromb Vasc Biol (1996) 1.55

Computer programs to identify and classify amphipathic alpha helical domains. J Lipid Res (1992) 1.54

Membrane interactions of synthetic peptides corresponding to amphipathic helical segments of the human immunodeficiency virus type-1 envelope glycoprotein. J Biol Chem (1992) 1.53

A new synthetic class A amphipathic peptide analogue protects mice from diet-induced atherosclerosis. J Lipid Res (2001) 1.53

Cytosolic domain of the human immunodeficiency virus envelope glycoproteins binds to calmodulin and inhibits calmodulin-regulated proteins. J Biol Chem (1993) 1.50

Two apolipoprotein E mimetic peptides with similar cholesterol reducing properties exhibit differential atheroprotective effects in LDL-R null mice. Atherosclerosis (2012) 1.50

Mechanisms for the modulation of membrane bilayer properties by amphipathic helical peptides. Biopolymers (1995) 1.48

Structure and function of HDL mimetics. Arterioscler Thromb Vasc Biol (2009) 1.40

Plasma concentrations of inflammatory cytokines rise rapidly during ECMO-related SIRS due to the release of preformed stores in the intestine. Lab Invest (2009) 1.40

Interactions of synthetic peptide analogs of the class A amphipathic helix with lipids. Evidence for the snorkel hypothesis. J Biol Chem (1994) 1.39

A novel method for oral delivery of apolipoprotein mimetic peptides synthesized from all L-amino acids. J Lipid Res (2009) 1.37

Influenza infection promotes macrophage traffic into arteries of mice that is prevented by D-4F, an apolipoprotein A-I mimetic peptide. Circulation (2002) 1.37

Double belt structure of discoidal high density lipoproteins: molecular basis for size heterogeneity. J Mol Biol (2004) 1.36

Inhibition of lipopolysaccharide-induced inflammatory responses by an apolipoprotein AI mimetic peptide. Circ Res (2005) 1.35

Apolipoprotein A-I mimetic peptides and their role in atherosclerosis prevention. Nat Clin Pract Cardiovasc Med (2006) 1.33

Janus kinase 2 modulates the lipid-removing but not protein-stabilizing interactions of amphipathic helices with ABCA1. J Lipid Res (2005) 1.30

Bioactivity of peptide analogs of the neutrophil chemoattractant, N-acetyl-proline-glycine-proline. Invest Ophthalmol Vis Sci (1999) 1.28

Influence of apoE domain structure and polymorphism on the kinetics of phospholipid vesicle solubilization. J Lipid Res (2002) 1.27

Synthetic amphipathic helical peptides that mimic apolipoprotein A-I in clearing cellular cholesterol. J Clin Invest (1994) 1.26

Truncation of the amino terminus of human apolipoprotein A-I substantially alters only the lipid-free conformation. Biochemistry (1997) 1.25

Efflux of cellular cholesterol and phospholipid to lipid-free apolipoproteins and class A amphipathic peptides. Biochemistry (1995) 1.25

D-4F reduces EO6 immunoreactivity, SREBP-1c mRNA levels, and renal inflammation in LDL receptor-null mice fed a Western diet. J Lipid Res (2007) 1.23

The lipid-free structure of apolipoprotein A-I: effects of amino-terminal deletions. Biochemistry (1998) 1.22

Intestine may be a major site of action for the apoA-I mimetic peptide 4F whether administered subcutaneously or orally. J Lipid Res (2011) 1.22

Molecular basis for prokaryotic specificity of magainin-induced lysis. Biochemistry (1995) 1.21

D-4F, an apolipoprotein A-I mimetic peptide, inhibits the inflammatory response induced by influenza A infection of human type II pneumocytes. Circulation (2004) 1.20

Turnover of synthetic class A amphipathic peptide analogues of exchangeable apolipoproteins in rats. Correlation with physical properties. Arterioscler Thromb (1992) 1.19

Structural models of human apolipoprotein A-I. Biochim Biophys Acta (1995) 1.19

Apolipoprotein-mediated plasma membrane microsolubilization. Role of lipid affinity and membrane penetration in the efflux of cellular cholesterol and phospholipid. J Biol Chem (1999) 1.19

HDL as a biomarker, potential therapeutic target, and therapy. Diabetes (2009) 1.19

Effect of end group blockage on the properties of a class A amphipathic helical peptide. Proteins (1993) 1.19

The role of high-density lipoprotein in inflammation. Trends Cardiovasc Med (2005) 1.17

Sequence conservation of apolipoprotein A-I affords novel insights into HDL structure-function. J Lipid Res (2010) 1.17

ApoA-I mimetic peptides with differing ability to inhibit atherosclerosis also exhibit differences in their interactions with membrane bilayers. J Biol Chem (2006) 1.16

Influence of ApoA-I structure on the ABCA1-mediated efflux of cellular lipids. J Biol Chem (2004) 1.15

Aromatic residue position on the nonpolar face of class a amphipathic helical peptides determines biological activity. J Biol Chem (2004) 1.15

Apolipoprotein E mimetic Peptide dramatically lowers plasma cholesterol and restores endothelial function in watanabe heritable hyperlipidemic rabbits. Circulation (2005) 1.14

Association of aortic atherosclerosis with cerebral beta-amyloidosis and learning deficits in a mouse model of Alzheimer's disease. Am J Pathol (2003) 1.14

Apolipoprotein A-I mimetic peptides. Curr Atheroscler Rep (2009) 1.13

Synthetic peptide analogs of apolipoproteins. Methods Enzymol (1986) 1.13

Structure and function of apolipoprotein A-I and high-density lipoprotein. Curr Opin Lipidol (2000) 1.13

D-4F-mediated reduction in metabolites of arachidonic and linoleic acids in the small intestine is associated with decreased inflammation in low-density lipoprotein receptor-null mice. J Lipid Res (2011) 1.13

Apolipoprotein A-I and its amphipathic helix peptide analogues inhibit human immunodeficiency virus-induced syncytium formation. J Clin Invest (1990) 1.13

Apolipoprotein A-I mimetic 4F alters the function of human monocyte-derived macrophages. Am J Physiol Cell Physiol (2010) 1.12

An oral apoJ peptide renders HDL antiinflammatory in mice and monkeys and dramatically reduces atherosclerosis in apolipoprotein E-null mice. Arterioscler Thromb Vasc Biol (2005) 1.12

L-5F, an apolipoprotein A-I mimetic, inhibits tumor angiogenesis by suppressing VEGF/basic FGF signaling pathways. Integr Biol (Camb) (2011) 1.11

D-4F decreases brain arteriole inflammation and improves cognitive performance in LDL receptor-null mice on a Western diet. J Lipid Res (2006) 1.10

Osmotically induced membrane tension modulates membrane permeabilization by class L amphipathic helical peptides: nucleation model of defect formation. Biophys J (2001) 1.10

The receptor binding domain of apolipoprotein E, linked to a model class A amphipathic helix, enhances internalization and degradation of LDL by fibroblasts. Biochemistry (2000) 1.10

A novel approach to oral apoA-I mimetic therapy. J Lipid Res (2013) 1.09

apoB-100 has a pentapartite structure composed of three amphipathic alpha-helical domains alternating with two amphipathic beta-strand domains. Detection by the computer program LOCATE. Arterioscler Thromb (1994) 1.08

Apolipoprotein A-I mimetic peptide treatment inhibits inflammatory responses and improves survival in septic rats. Am J Physiol Heart Circ Physiol (2009) 1.07